Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics

doi:10.1053/j.gastro.2006.09.052

Gastroenterology

Volume 131, Issue 6, December 2006, Pages 1887-1898

https://doi.org/10.1053/j.gastro.2006.09.052 Get rights and content

Background & Aims: Hepatitis C virus (HCV) is a major cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma. Current therapy with pegylated interferon α (IFN-α) in combination with ribavirin is associated with adverse effects and often fails to induce a sustained response. IFN-λs, recently discovered IFN gene family members, exhibit antiviral and cell stimulatory activities similar to IFN-α. We aimed to determine whether IFN-λ exhibits antiviral activity toward HCV and to compare the signal transduction and effector gene pathways with those of IFN-α. Methods: Using the HCV replicon system and cell culture infectious reporter virus, we compared IFN-α and IFN-λ effects on HCV RNA replication and protein expression, as measured by quantitative reverse-transcriptase polymerase chain reaction, luciferase expression, and Western blot. Receptor expression and signaling pathways were explored using flow cytometry and Western blot. IFN-α- and IFN-λ-mediated gene expression changes were compared using microarray analyses. Results: IFN-λ exhibited dose- and time-dependent HCV inhibition, independent of types I and II IFN receptors. The kinetics of IFN-λ-mediated signal transducers and activators of transcription (STAT) activation and induction of potential effector genes were distinct from those of IFN-α. IFN-λ induced steady increases in levels of known interferon stimulated genes (ISGs), whereas IFN-α ISGs peaked early and declined rapidly. IFN-λ inhibited replication of HCV genotypes 1 and 2 and enhanced the antiviral efficacy of subsaturating levels of IFN-α. Conclusions: These results demonstrate distinct differences in IFN-λ- and IFN-α-induced antiviral states. Understanding these differences may prove useful for developing new HCV treatment strategies.

Section snippets

Cell Cultures and Replicon-Containing Cells

Huh-7.5 monolayers were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco) and 0.1 mmol/L MEM nonessential amino acid solution (Gibco) at 37°C in a humidified atmosphere of 5% CO₂. For cells supporting full-length HCV replicons, G418 (Gibco) at 750 μg/mL was added to the culture medium. The full-length HCV Con1 (genotype 1b) bicistronic replicon shown in Figure 1A was used for all replicon

Inhibition of HCV RNA and Protein Accumulation by IFN-λ Is Dose Dependent

The observation that IFN-λs have an antiviral effect on cells infected with EMCV or VSV prompted us to evaluate whether an inhibitory effect could also be seen on HCV RNA replication in cell culture. Fl-neo cells were cultured in plain media for 24 hours prior to incubation with IFN-λ or IFN-α at various concentrations for 48 hours. No alterations in cell growth or morphology were apparent except for a slight decrease in confluency seen with the highest IFN doses. Total RNA was prepared, and

Discussion

The in vivo biologic role of IFN-λ remains to be understood. Upon viral challenge, or through stimulation of TLR-9, dendritic cells (DCs) express IFN-λ together with type I IFNs.⁴⁵ Plasmacytoid DCs produce 100-fold higher levels of IFN-λ transcript when compared with monocyte-derived DCs. The biologic effects of IFN-λ and IFN-α depend not only on the levels produced but also on the cellular distribution and levels of their respective functional receptor complexes. Whereas type I IFN receptors

References (53)

M. Frese et al.
Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs
Hepatology
(2002)
C.A. Benedict
Viruses and the TNF-related cytokines, an evolving battle
Cytokine Growth Factor Rev
(2003)
J.A. Langer et al.
The class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions
Cytokine Growth Factor Rev
(2004)
S.V. Kotenko et al.
Full house: 12 receptors for 27 cytokines
Int Immunopharmacol
(2004)
C.V. Ramana et al.
Stat1-dependent and -independent pathways in IFN-γ-dependent signaling
Trends Immunol
(2002)
M. Gale
Effector genes of interferon action against hepatitis C virus
Hepatology
(2003)
M.R. Rani et al.
Characterization of β-R1, a gene that is selectively induced by interferon β (IFN-β) compared with IFN-α
J Biol Chem
(1996)
S. Brand et al.
SOCS-1 inhibits expression of the antiviral proteins 2’,5’-OAS and MxA induced by the novel interferon-λs IL-28A and IL-29
Biochem Biophys Res Commun
(2005)
S. Radaeva et al.
Interferon-α activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes
Gastroenterology
(2002)
L. Dumoutier et al.
Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-(λ)1: similarities with type I interferon signaling
J Biol Chem
(2004)

E. Dondi et al.

J Virol

(2003)

Cited by (532)

The role and application of three IFN-related reactions in psoriasis
2023, Biomedicine and Pharmacotherapy
The pathophysiology of psoriasis is a highly complicated one. Due to the disease's specificity, it not only affects the patient's skin negatively but also manifests systemic pathological changes. These clinical symptoms seriously harm the patient's physical and mental health. IFN, a common immunomodulatory factor, has been increasingly demonstrated to have a significant role in the development of psoriatic skin disease. Psoriasis is connected with a variety of immunological responses. New targets for the therapy of autoimmune skin diseases may emerge from further research on the mechanics of the associated IFN upstream and downstream pathways. Different forms of IFNs do not behave in the same manner in psoriasis, and understanding how different types of IFNs are involved in psoriasis may provide a better notion for future research. This review focuses on the involvement of three types of IFNs in psoriasis and related therapeutic investigations, briefly describing the three IFNs' production and signaling, as well as the dual effects of IFNs on the skin. It is intended that it would serve as a model for future research.
Interferon lambda modulates proinflammatory cytokines production in PBMCs from patients with chronic kidney disease
2023, Human Immunology
CKD is a major cause of morbidity and mortality worldwide. Considerable evidence now indicates that renal inflammation plays a central role in the initiation and progression of CKD. Recent investigations have demonstrated that IFNλ plays an important role in the pathogenesis of autoimmune and inflammatory diseases. However, the association of IFNλ with CKD is still poorly understood.
To analyze the correlation between IFNλ levels and pro-inflammatory cytokines, and to investigate the effect of IFNλ on PBMCs in patients with CKD.
PBMCs were harvested from patients with CKD and healthy controls for measuring the expression level of inflammatory cytokines by RT-qPCR. Spearman correlation test was used to analyze correlation between IFNλ and cytokines as well as eGFR. PBMCs from healthy individuals and CKD patients were subjected to IFNλ protein stimulation. IL6, TNFα, IL10, ISG15 and MX1 mRNA level were measured by RT-PCR, STAT1 and phosphorylated STAT1 protein level were measured by Western blot.
Patients with CKD showed higher levels of IFNλ in PBMCs compared to healthy controls. IFNλ mRNA levels were associated with cytokines and eGFR. The transcription of IL6, TNFα, and IL10 was significantly increased in healthy human PBMCs after IFNλ stimulation. In addition, IFNλ acts on PBMCs by p-STAT1 and ISG15 as well as MX1.
High expression of IFNλ was found in CKD patients and was associated with eGFR and disease-related cytokines. More importantly, IFNλ promoted the expression of pro-inflammatory cytokines in PBMCs, suggesting a potential pro-inflammatory role of IFNλ in CKD.
Liver fibrosis in fish research: From an immunological perspective
2023, Fish and Shellfish Immunology
Liver fibrosis is a pathological process whereby the liver is subjected to various acute and chronic injuries, resulting in the activation of hepatic stellate cells (HSCs), an imbalance of extracellular matrix generation and degradation, and deposition in the liver. This review article summarizes the current understanding of liver fibrosis in fish research. Liver fibrosis is a common pathological condition that occurs in fish raised in aquaculture. It is often associated with poor water quality, stressful conditions, and the presence of pathogens. The review describes the pathophysiology of liver fibrosis in fish, including the roles of various cells and molecules involved in the development and progression of the disease. The review also covers the various methods used to diagnose and assess the severity of liver fibrosis in fish, including histological analysis, biochemical markers, and imaging techniques. In addition, the article discusses the current treatment options for liver fibrosis in fish, including dietary interventions, pharmaceuticals, and probiotics. This review highlights the need for more in-depth research in this area to better understand the mechanisms by which liver fibrosis in fish occurs and to develop effective prevention and treatment strategies. Finally, improved management practices and the development of new treatments will be critical to the sustainability of aquaculture and the health of farmed fish.
Zebrafish-based platform for emerging bio-contaminants and virus inactivation research
2023, Science of the Total Environment
Emerging bio-contaminants such as viruses have affected health and environment settings of every country. Viruses are the minuscule entities resulting in severe contagious diseases like SARS, MERS, Ebola, and avian influenza. Recent epidemic like the SARS-CoV-2, the virus has undergone mutations strengthen them and allowing to escape from the remedies. Comprehensive knowledge of viruses is essential for the development of targeted therapeutic and vaccination treatments. Animal models mimicking human biology like non-human primates, rats, mice, and rabbits offer competitive advantage to assess risk of viral infections, chemical toxins, nanoparticles, and microbes. However, their economic maintenance has always been an issue. Furthermore, the redundancy of experimental results due to aforementioned aspects is also in examine. Hence, exploration for the alternative animal models is crucial for risk assessments. The current review examines zebrafish traits and explores the possibilities to monitor emerging bio-contaminants. Additionally, a comprehensive picture of the bio contaminant and virus particle invasion and abatement mechanisms in zebrafish and human cells is presented. Moreover, a zebrafish model to investigate the emerging viruses such as coronaviridae and poxviridae has been suggested.
Pharmacogenomics in viral diseases
2023, Pharmacogenomics: from Discovery to Clinical Implementation
Viral diseases are the prominent infectious diseases that constitute the leading cause of death globally. Among the viral diseases, the commonly found diseases in humans include common cold, flu, hepatitis, chickenpox, Ebola, COVID-19, and AIDS. Hepatitis A virus affects more than 80% of the population, incuding hepatitis B (360 million), hepatitis C virus (123 million), and HIV (30 million) worldwide. As a result, millions of people around the world are still battling for their survival. Smallpox, chickenpox, dengue, and other lethal diseases have been conquered thanks to advancements in medical research, but unexpectedly, hepatitis, influenza, and HIV viruses have posed new challenges. The absence of vaccinations, harmful drug reactions, the occurrence of antibiotic resistance variants of common organisms as a result of antibiotic abuse, and susceptibility issues are few of the therapy's problems and roadblocks. The human genome project's finding has created new avenues for research into how genetic makeup affects disease development and progression, as well as therapeutic options for numerous viral diseases. New antiviral therapeutic medicines have significantly improved survival rates overall, but this success has fallen short of expectations because some people have experienced negative side effects from these medications. The current burden of viral diseases may be reduced with the help of pharmacogenomics research and knowledge development. As a result, choosing the best treatment agents, dosages, and drug response for each person will undoubtedly be made easier. Hence, it will become possible to translate the lab studies to clinical bench side, which will aid in gaining proper knowledge of etiology of various diseases of virus with therapeutic action, allowing for better patient management and ultimately enabling the fulfillment of the future's promise.
Enhanced TLR3 responsiveness in hepatitis C virus resistant women from the Irish anti-D cohort
2022, Cell Reports Medicine
Natural resistance to infection is an overlooked outcome after hepatitis C virus (HCV) exposure. Between 1977 and 1979, 1,200 Rhesus D-negative Irish women were exposed to HCV-contaminated anti-D immunoglobulin. Here, we investigate why some individuals appear to resist infection despite exposure (exposed seronegative [ESN]). We screen HCV-resistant and -susceptible donors for anti-HCV adaptive immune responses using ELISpots and VirScan to profile antibodies against all know human viruses. We perform standardized ex vivo whole blood stimulation (TruCulture) assays with antiviral ligands and assess antiviral responses using NanoString transcriptomics and Luminex proteomics. We describe an enhanced TLR3-type I interferon response in ESNs compared with seropositive women. We also identify increased inflammatory cytokine production in response to polyIC in ESNs compared with seropositive women. These enhanced responses may have contributed to innate immune protection against HCV infection in our cohort.

View all citing articles on Scopus

: Supported in part by United States Public Health Services grant RO1 AI51139 from the National Institute of Allergy and Infectious Diseases and by the American Heart Association grant AHA 0245131N (to S.V.K.); by a Cancer Research Institute Investigator Award, The Robert W. Woodruff Health Sciences Foundation and Yerkes Research Center base grant RR-00165 (to A.G.); and by grants from the National Institutes of Health and the Greenberg Medical Research Institute (to C.M.R.).

¹: T.M.’s present address is Klinikum Sankt Georg Leipzig, Second Department of Internal Medicine, Delitzscher Street 141, 04129 Leipzig, Germany.

²: G.B-S.’s present address is Structural Virology, Pasteur Institute, 25-28 rue du Docteur Roux, 75015 Paris, France.

³: T.M. and A.G. contributed equally to this work.

View full text

Basic–liver, pancreas, and biliary tractInterferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics

Section snippets

Cell Cultures and Replicon-Containing Cells

Inhibition of HCV RNA and Protein Accumulation by IFN-λ Is Dose Dependent

Discussion

Hepatology

Cytokine Growth Factor Rev

Cytokine Growth Factor Rev

Int Immunopharmacol

Trends Immunol

Hepatology

J Biol Chem

Biochem Biophys Res Commun

Gastroenterology

J Biol Chem

J Biol Chem

Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease

MMWR Recomm Rep

The natural history of community-acquired hepatitis C in the United States

N Engl J Med

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

N Engl J Med

Hepatitis C virus and organ transplantation

Transplantation

Therapy of hepatitis C: α interferon and ribavirin

Hepatology

Improved biological and transcriptional activity of monopegylated interferon-α-2a isomers

Pharmacogenomics J

Hepatitis C advances in antiviral therapy: what is accepted treatment now?

J Gastroenterol Hepatol

Unravelling hepatitis C virus replication from genome to function

Nature

Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by α, β, and γ interferons

J Virol

Hepatitis C virus RNA replication is resistant to tumour necrosis factor-α

J Gen Virol

Interferon-α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway

J Gen Virol

Effect of α interferon on the hepatitis C virus replicon

J Virol

Antiviral effect and virus-host interactions in response to α interferon, γ interferon, poly(i)-poly(c), tumor necrosis factor α, and ribavirin in hepatitis C virus subgenomic replicons

J Virol

Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication

J Virol

Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway

J Virol

Basic–liver, pancreas, and biliary tract
Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics